Home > Boards > US Listed > Medical - Drugs > Sol Gel Technologies Ltd (SLGL)

Thanks Midas for starting the mb here. As I

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Amatuer17 Member Profile
 
Followed By 68
Posts 11,576
Boards Moderated 0
Alias Born 04/03/14
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/22/2021 1:25:07 PM
Raymond James: These 3 Stocks Are Poised to Surge by at Least 50% TipRanks - 3/10/2021 10:29:53 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/9/2021 1:07:46 PM
Sol-Gel Technologies reports FY 2020 results Seeking Alpha - 3/4/2021 7:55:57 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/4/2021 7:43:55 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/4/2021 7:38:05 AM
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update GlobeNewswire Inc. - 3/4/2021 7:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/1/2021 6:32:50 AM
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global ... GlobeNewswire Inc. - 2/24/2021 7:05:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/11/2021 11:13:48 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/5/2021 6:06:42 AM
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Co... GlobeNewswire Inc. - 1/11/2021 7:05:00 AM
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulga... GlobeNewswire Inc. - 12/7/2020 7:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 9:12:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 9:08:36 AM
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update GlobeNewswire Inc. - 11/12/2020 7:05:00 AM
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020 GlobeNewswire Inc. - 11/9/2020 7:05:00 AM
Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020 GlobeNewswire Inc. - 11/4/2020 4:05:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/14/2020 9:14:10 AM
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammat... GlobeNewswire Inc. - 9/10/2020 4:01:10 PM
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September GlobeNewswire Inc. - 9/8/2020 7:05:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/3/2020 8:41:29 AM
Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii® GlobeNewswire Inc. - 9/3/2020 7:05:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 10:40:18 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 10:37:55 AM
Amatuer17   Tuesday, 04/14/20 05:55:44 AM
Re: midastouch017 post# 1
Post # of 36 
Thanks Midas for starting the mb here.

As I mention I like the co for few reasons

1. It has 2 NDAs coming in next 6 months
2. Many small companies are getting hit by clinical trial delays. This co is out of it.
3. The clinical trial delays are going to be long, hospitals will take many months to come back to normal and start the trials back, in some cases enroll more patients as some of the patients have lost few follow up visits.
Based on this I am focused on small pharma or biotechs who have finished their trials or submitted NDAs
4. The co has money to sustain
5. The 2 drugs of approved will become new SOC. Both indications are facial ones so it has ready market and will have pricing power.

The key is - investor has to hold for at least 1 year for first approval and another 6 months for next approval. During this period one can get this stock at lower price as well.

At $168 million market cap it has at least 3 bagger potential in mind from current price in 2 years.


“Our goals for 2020 are no less ambitious as we plan to file two New Drug Applications (NDA) in the U.S. – Epsolay in the second quarter of 2020 and Twyneo in the second half. In parallel, we are planning commercialization efforts and advancing development of our proprietary pipeline, while benefiting from our strong generic collaborations.” “
In terms of COVID-19 impact,” continued Dr. Seri-Levy, “given that Sol-Gel has completed the clinical programs required to support the NDAs for both Epsolay and Twyneo, and given that Sol-Gel recently strengthened its balance sheet, we remain on track to file both NDAs in the previously communicated timelines.”

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences